Performance of the CARDIOGARD Cannula (GECG)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02764645
Recruitment Status : Not yet recruiting
First Posted : May 6, 2016
Last Update Posted : May 6, 2016
CardioGard Medical Ltd.
Information provided by (Responsible Party):
Gil Bolotin MD, Rambam Health Care Campus

Brief Summary:

This is a single center, prospective study:

The 'CardioGard Cannula' Gaseous emboli capture results - shows an improvement from the control group.

Condition or disease Intervention/treatment Phase
Heart Valve Diseases Coronary Artery Disease Device: CardioGard Cannula Device: 22Fr curved Cannula Not Applicable

Detailed Description:

Patients referred for CPB procedure will be offered to participate in the study. Patients will be asked to sign an informed consent form (ICF), prior to performing any study related procedures.

The point of enrollment is the time at which a patient signs and dates the ICF. Following enrollment, the patient will undergo screening evaluation (including Neurological assessment) to determine eligibility. Screening failures will be identified on a screening log. Patients who are found to meet all inclusion criteria and none of the exclusion criteria will compose the evaluable cohort of the study. Screening failure subjects will not be counted as part of the target patient sample size nor will they be included in the analysis.

Patients in the randomized phase will have surgery with the CardioGard Cannula or comparator cannulae and will remain blinded to their group assignment through the 30 days follow-up evaluation.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 400 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Prevention
Official Title: A Study to Collect Additional Information Related to the Performance of the CARDIOGARD Cannula
Study Start Date : May 2016
Estimated Primary Completion Date : May 2017
Estimated Study Completion Date : May 2019

Arm Intervention/treatment
Experimental: CardioGard group

Patients in whom the CardioGard Cannula will be used, while In these patients there would be a measurement of the gaseous emboli in two points: 1. The aortic vent.

2. The suction cannula of the 'Cardiogard cannula'.

Device: CardioGard Cannula

CardioGard Cannula is a specially designed arterial (aortic) cannula for use in cardiac surgery for the purpose of removal of gaseous and solid embolic material emanating during the CPB procedure.

The CardioGard cannula is a double lumen cannula where the primary lumen provides blood from the heart-lung machine similar to ordinary cannulas and the secondary lumen performs suction of blood and embolic matter away from the aortic arch and back to the cardiopulmonary bypass machine for filtration.

Active Comparator: Control group
Patients in whom a 22Fr curved Cannula will be used, while In these patients there would be a measurement of the gaseous emboli in the aortic vent alone.
Device: 22Fr curved Cannula
arterial cannula for use in cardiac surgery

Primary Outcome Measures :
  1. The 'CardioGard Cannula' Gaseous emboli capturing ability [ Time Frame: 36 months ]
    The gaseous emboli capturing ability of the cardiogard cannula will be evaluated using a bubbles counter. .

Secondary Outcome Measures :
  1. The amount of emboli particles which evacuated from the cardiopulmonarybypass machine by the CardioGard Cannula [ Time Frame: 36 months ]
    Using the suction feature, External filters will be analyzed in order to recover particulate matter.

  2. The Neurological effect of reducing gaseous emboli from the heart during cardiac surgery. [ Time Frame: 36 months ]
    The ability of the Cardiogard cannula will be evaluated using Neurological questionnaires.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   50 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  1. Patient indicated for first-time non-emergent procedure under cardiopulmonary bypass which is expected to last up to 6 hours.
  2. Patient undergoing an elective isolated coronary artery bypass surgery (CABG), or an elective isolated aortic/mitral valve replacement (AVR/MVR) or an elective combined aortic/mitral valve replacement (AVR/MVR) with coronary artery bypass surgery (CABG).
  3. The patient is >50 and <85 years of age.
  4. The patient's body weight is compatible with blood net flow of 4 - 5 [l/min].
  5. Patient with left ventricular ejection fraction >30% as assessed by either echocardiography, angiography or by radio nuclear assessment (MUGA)
  6. The patient is willing to participate as evidenced by signing the written informed consent.
  7. Male or non-pregnant female patient (Note: Females of child bearing potential must have a negative pregnancy test)

Exclusion Criteria:

  1. Patient with abnormal clotting mechanism: PT 60%, PTT>2 the normal.
  2. Patient with an aortic trauma.
  3. Patient contraindicated for open heart surgery under bypass machine.
  4. Patient undergoing a re-do procedure.
  5. Patient intended for an operation performed using minimally invasive surgical techniques (e.g., mini-sternotomy)
  6. Patient with pathologies which affect his/her neurological condition.
  7. Patient in whom emergency operation is required.
  8. Patient with a known allergy to Heparin
  9. Patient with major co-morbid condition(s) that could limit the patient's ability to participate in the study, or impact the scientific integrity of the study, including but not limited to:

    • previous stroke
    • critical preoperative state
    • poor ventricular function
    • severe pulmonary hypertension [19]
    • Atheroembolism
    • history of cardiac failure [20]
  10. Current use of drugs that might result in high surgical risk or significant postoperative complication.
  11. Psychological instability, inappropriate attitude or motivation.
  12. Patients with life threatening debilitating disease other than cardiac.
  13. Subjects currently enrolled in another investigational device or drug trial that has not completed the primary end point or that clinically interferes with the current study endpoints.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02764645

Contact: Roi - Glam, MD +972-4-7772631
Contact: Daniel - Haber, MA +972-4-7772048

Sponsors and Collaborators
Rambam Health Care Campus
CardioGard Medical Ltd.
Principal Investigator: Gil - Bolotin, Prof. Head of the Cardiac Surgery Department, Rambam Health Care Campus

Responsible Party: Gil Bolotin MD, Professor, Rambam Health Care Campus Identifier: NCT02764645     History of Changes
Other Study ID Numbers: CLNG100 Full Protocol
First Posted: May 6, 2016    Key Record Dates
Last Update Posted: May 6, 2016
Last Verified: May 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: The data of this research would be published as an article and will include all the relevant clinical outcomes related to the effect of gaseous emboli.

Keywords provided by Gil Bolotin MD, Rambam Health Care Campus:
Cardiopulmonary Bypass

Additional relevant MeSH terms:
Coronary Artery Disease
Myocardial Ischemia
Coronary Disease
Heart Valve Diseases
Heart Diseases
Cardiovascular Diseases
Arterial Occlusive Diseases
Vascular Diseases